The Latest Breaking News from Amgen

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Learn how diversification, careful screening, and key metrics like payout ratios and yields can help build a strong, income-generating portfolio for the long term.

Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.

Despite pharma giant Amgen trailing behind the Dow index over the past three months, analysts remain cautiously bullish about the stock's growth potential.

Stocks generally enjoyed one of the best months of the year. Here's what else you should know about the markets into year-end.

Even though Amgen is weak below the 200-day line, there's still a way to profit.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Most indexes hit new highs during Thanksgiving week despite President-elect Trump's tariff threats. Nvidia woes helped curb the Nasdaq's gains.

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.